ALTO-101
Cognitive Impairment Associated with Schizophrenia (CIAS)
Key Facts
About Alto Neuroscience
Alto Neuroscience is a precision psychiatry company leveraging a proprietary AI-driven biomarker platform to develop targeted therapies for major depressive disorder, bipolar depression, and schizophrenia. Founded in 2019 and built on 15 years of foundational neurobiology research, the company has rapidly advanced a multi-asset clinical pipeline. Its core strategy is to use objective measures of brain function to identify patient subpopulations most likely to respond to its novel drug candidates, thereby increasing clinical success rates and commercial potential.
View full company profileAbout Alto Neuroscience
Alto Neuroscience is a precision psychiatry company leveraging a proprietary AI-driven biomarker platform to develop targeted therapies for major depressive disorder, bipolar depression, and schizophrenia. Founded in 2019 and built on 15 years of foundational neurobiology research, the company has rapidly advanced a multi-asset clinical pipeline. Its core strategy is to use objective measures of brain function to identify patient subpopulations most likely to respond to its novel drug candidates, thereby increasing clinical success rates and commercial potential.
View full company profileTherapeutic Areas
Other Cognitive Impairment Associated with Schizophrenia (CIAS) Drugs
| Drug | Company | Phase |
|---|---|---|
| RL-007 | Recognify Life Sciences | Phase 2 |